EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische Studie

The Impact of PSMA PET–Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy

Amir Karimzadeh, Matthias Heck, Robert Tauber, Esteban Solaris, Stephan Nekolla, Karina Knorr, Bernhard Haller, Calogero D'Alessandria, Wolfgang A Weber, Matthias Eiber, Isabel Rauscher

Journal of Nuclear Medicine · 2023-08 · 64 (8) · 1252-1258

DOI: 10.2967/jnumed.122.265346 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 08.06.2023. Verfasst von Amir Karimzadeh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany; amir.karimzadeh@uke.de. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantMaleHumansProstate-Specific AntigenTreatment OutcomeFluorodeoxyglucose F18Prospective StudiesProstateDipeptidesHeterocyclic Compounds, 1-RingLutetiumRetrospective Studies

Stichwörter der Autor:innen

68Ga-PSMA-11 PETPSMA RLTTheraPmCRPCmetastatic castration-resistant prostate cancerprostate-specific membrane antigen targeted radioligand therapy

Substanzen

Prostate-Specific AntigenFluorodeoxyglucose F18DipeptidesHeterocyclic Compounds, 1-RingLutetium

Autor:innen und Institutionen

  • Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany; amir.karimzadeh@uke.de.
  • Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Urology, School of Medicine, Technical University of Munich, Munich, Germany; and.
  • Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany.
  • Institute of AI and Informatics in Medicine, School of Medicine, Technical University of Munich, Munich, Germany.

Zitieren

APA

Karimzadeh, A., Heck, M., Tauber, R., Solaris, E., Nekolla, S., Knorr, K., Haller, B., D'Alessandria, C., Weber, W. A., Eiber, M., & Rauscher, I. (2023). The Impact of PSMA PET–Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy. Journal of Nuclear Medicine, 64(8), 1252-1258. https://doi.org/10.2967/jnumed.122.265346

Vancouver

Karimzadeh A, Heck M, Tauber R, Solaris E, Nekolla S, Knorr K, et al. The Impact of PSMA PET–Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy. Journal of Nuclear Medicine. 2023;64(8):1252-1258. doi:10.2967/jnumed.122.265346

BibTeX
@article{Karimzadeh2023,
  author = {Karimzadeh, Amir and Heck, Matthias and Tauber, Robert and Solaris, Esteban and Nekolla, Stephan and Knorr, Karina and Haller, Bernhard and D'Alessandria, Calogero and Weber, Wolfgang A and Eiber, Matthias and Rauscher, Isabel},
  title = {The Impact of PSMA PET–Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {8},
  pages = {1252--1258},
  doi = {10.2967/jnumed.122.265346}
}
Kostenlos starten →